최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기한국임상약학회지 = Korean journal of clinical pharmacy, v.30 no.1, 2020년, pp.31 - 35
이경주 (강원대학교 약학대학) , 김경림 (강원대학교 약학대학) , 성재민 (강원대학교 약학대학) , 유승완 (강원대학교 약학대학) , 이현윤 (강원대학교 약학대학) , 조세경 (강원대학교 약학대학) , 정예지 (강원대학교 약학대학) , 남기남 (강원대학교 약학대학) , 이유정 (강원대학교 약학대학)
Objective: The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are frequently prescribed medications worldwide for the treatment of hypercholesterolemia. Statins are considered to be well tolerated; however, they have a potential for myotoxicity. Concomitant drugs that inhibit c...
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
Statins는 무슨 역할을 하는가? | HMG CoA-reductase inhibitors (statins)는 전세계적으로 이상지질혈증을 포함한 심혈관계 질환 환자에게 널리 처방되는 약물이다.1) Statins는 관상동맥질환의 위험이 있는 환자들의 low-density lipoprotein cholesterol (LDL-C) 수치를 효과적으로 감소시켜 심혈관계 질환으로 인한 사망률을 감소시킨다.2)일반적으로 statins는 비교적 안전하게 사용이 가능한 약물이 지만, 간기능 장애 및 근육관련 이상반응이 나타날 수 있다. | |
statins는 무엇인가? | HMG CoA-reductase inhibitors (statins)는 전세계적으로 이상지질혈증을 포함한 심혈관계 질환 환자에게 널리 처방되는 약물이다.1) Statins는 관상동맥질환의 위험이 있는 환자들의 low-density lipoprotein cholesterol (LDL-C) 수치를 효과적으로 감소시켜 심혈관계 질환으로 인한 사망률을 감소시킨다. | |
statins의 어떤 것들이 CYP에 의해 대사되는가? | 대부분의 statins는 cytochrome P450 (CYP)에 의한 대사과 정을 거친다.9) 특히 atorvastatin, simvastatin, lovastatin은 주로 CYP 3A4에 의하여 대사된다.9) 따라서 CYP 3A4 inhibitors 약물과 atorvastatin, simvastatin, 또는 lovastatin을 동시에 복용할 경우 statins의 혈중농도 상승을 야기하여 간기능 장애 및 근육과 관련한 부작용 발생의 위험이 증가한다. |
Catapano, Alberico L., Graham, Ian, De Backer, Guy, Wiklund, Olov, Chapman, M. John, Drexel, Heinz, Hoes, Arno W., Jennings, Catriona S., Landmesser, Ulf, Pedersen, Terje R., Reiner, Željko, Riccardi, Gabriele, Taskinen, Marja-Riita, Tokgozoglu, Lale, Verschuren, W. M. Monique, Vlachopoulos, Charalambos, Wood, David A., Zamorano, Jose Luis. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European heart journal, vol.37, no.39, 2999-3058.
Bellosta, Stefano, Corsini, Alberto. Statin drug interactions and related adverse reactions: an update. Expert opinion on drug safety, vol.17, no.1, 25-37.
Cziraky, Mark J., Willey, Vincent J., McKenney, James M., Kamat, Siddhesh A., Fisher, Maxine D., Guyton, John R., Jacobson, Terry A., Davidson, Michael H.. Statin Safety: An Assessment Using an Administrative Claims Database. The American journal of cardiology, vol.97, no.8, S61-S68.
Omar, Mohamed A, Wilson, James P, Cox, Tamara S. Rhabdomyolysis and HMG-CoA Reductase Inhibitors. The Annals of pharmacotherapy, vol.35, no.9, 1096-1107.
Becker, Matthijs L, Kallewaard, Marjon, Caspers, Peter W J, Schalekamp, Tom, Stricker, Bruno H C. Potential Determinants of Drug-Drug Interaction Associated Dispensing in Community Pharmacies :. Drug safety : an international journal of medical toxicology and drug experience, vol.28, no.5, 371-378.
Shapiro LE, Shear NH. Drug-drug interactions: how scared should we be? CMAJ 1999;161(10):1266-7.
Bellosta, Stefano, Corsini, Alberto. Statin drug interactions and related adverse reactions. Expert opinion on drug safety, vol.11, no.6, 933-946.
Corsini, Alberto, Bellosta, Stefano. Drug-drug interaction with statins. Expert review of clinical pharmacology, vol.1, no.1, 105-113.
Schachter, Michael. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundamental & clinical pharmacology, vol.19, no.1, 117-125.
Bottorff, Michael B.. Statin Safety and Drug Interactions: Clinical Implications. The American journal of cardiology, vol.97, no.8, S27-S31.
Lexicomp. Lexi-comp Inc Web site. Available from https://online.lexi.com . Accessed November 27, 2019.
Tirkkonen, Tuire, Ryynänen, Anna, Vahlberg, Tero, Irjala, Kerttu, Klaukka, Timo, Huupponen, Risto, Laine, Kari. Frequency and Clinical Relevance of Drug Interactions with Lovastatin and Simvastatin : An Observational Database Study. Drug safety : an international journal of medical toxicology and drug experience, vol.31, no.3, 231-240.
Zhelyazkova-Savova, Maria, Gancheva, Silvia, Sirakova, Vera. Potential statin-drug interactions: prevalence and clinical significance. SpringerPlus, vol.3, no.1, 168-.
Ferri, Nicola, Corsini, Alberto, Bellosta, Stefano. Pharmacology of the New P2Y12 Receptor Inhibitors: Insights on Pharmacokinetic and Pharmacodynamic Properties. Drugs, vol.73, no.15, 1681-1709.
Janković, Slobodan M., Pejčić, Ana V., Milosavljević, Miloš N., Opančina, Valentina D., Pešić, Nikola V., Nedeljković, Tamara T., Babić, Goran M.. Risk factors for potential drug-drug interactions in intensive care unit patients. Journal of critical care, vol.43, 1-6.
Ismail, Mohammad, Iqbal, Zafar, Khattak, Muhammad Bilal, Khan, Muhammad Imran, Arsalan, Hassan, Javaid, Arshad, Gul, Qamar, Khan, Faramoz. Potential drug-drug interactions in internal medicine wards in hospital setting in Pakistan. International journal of clinical pharmacy, vol.35, no.3, 455-462.
You, Joyce H. S., Chan, Winnie K. Y., Chung, Polly F. P., Hu, Miao, Tomlinson, Brian. Effects of Concomitant Therapy with Diltiazem on the Lipid Responses to Simvastatin in Chinese Subjects. The Journal of clinical pharmacology, vol.50, no.10, 1151-1158.
Lewin III, John J, Nappi, Jean M, Taylor, Marian H. Rhabdomyolysis with Concurrent Atorvastatin and Diltiazem. The Annals of pharmacotherapy, vol.36, no.10, 1546-1549.
Mc Donnell, C. G., Harte, S., O'Driscoll, J., O'Loughlin, C., Van Pelt, F. D., Shorten, G. D.. The effects of concurrent atorvastatin therapy on the pharmacokinetics of intravenous midazolam. Anaesthesia, vol.58, no.9, 899-904.
Danielak, Dorota, Karaźniewicz-Łada, Marta, Główka, Franciszek. Assessment of the Risk of Rhabdomyolysis and Myopathy During Concomitant Treatment with Ticagrelor and Statins. Drugs, vol.78, no.11, 1105-1112.
Theetha Kariyanna, Pramod, Haseeb, Syed, Singh Chowdhury, Yuvraj, Jayarangaiah, Apoorva, Maryniak, Andrii, Mo, George, Hegde, Sudhanva, D. Marmur, Jonathan, M. McFarlane, Isabel.. Ticagrelor and Statin Interaction Induces Rhabdomyolysis and Acute Renal Failure: Case reports and Scoping Review. American journal of medical case reports, vol.7, no.12, 337-341.
Mrotzek, Simone M., Rassaf, Tienush, Totzeck, Matthias. Ticagrelor Leads to Statin-Induced Rhabdomyolysis: A Case Report. The American journal of case reports, vol.18, 1238-1241.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.